A detailed history of Macquarie Group LTD transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Macquarie Group LTD holds 142,393 shares of VRDN stock, worth $2.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
142,393
Previous 143,395 0.7%
Holding current value
$2.27 Million
Previous $3.26 Million 16.34%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$17.85 - $25.71 $17,885 - $25,761
-1,002 Reduced 0.7%
142,393 $2.73 Million
Q3 2024

Nov 14, 2024

BUY
$12.16 - $23.33 $1.39 Million - $2.66 Million
114,025 Added 388.24%
143,395 $3.26 Million
Q2 2024

Aug 09, 2024

BUY
$11.6 - $17.26 $340,692 - $506,926
29,370 New
29,370 $382,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $635M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.